CEP (CCNU, etoposide, and prednimustine) was tested as third-line chemotherapy in 40 patients resistant to both MOPP and ABVD. The observed response rate (complete remission, 35%, and partial remission, 25%) is encouraging. Treatment was generally well tolerated and all acute side effects were reversible.
|Number of pages||3|
|Journal||Seminars in Oncology|
|Issue number||1 SUPPL. 2|
|Publication status||Published - 1985|
ASJC Scopus subject areas